A meta-analysis of cyp2c19 gene testing on the prognosis of patients aged 60 years and older with acute coronary syndrome

Objective Whether cyp2c19 gene testing is clinically beneficial for patients aged 60 years and older with acute coronary syndrome. Methods A computerized search of WIFANG, CNKI, CBM and Vipul databases was performed to comprehensively collect RCTs on cyp2c19 gene-guided selection of different antiplatelet regimens or placebo or blank control comparisons. Results A total of 8 RCTs were included. cyp2c19 gene-guided prognosis regarding antiplatelet regimens in the elderly was better in the tigretol group than in the clopidogrel group, with statistically significant differences. CONCLUSION: Current evidence suggests that in the context of acute coronary syndromes in patients, with reference to the cyp2c19 gene and age, the overall clinical benefit of tigretol may be much better than clopidogrel, although patients may be at greater risk of bleeding.